China Medical System Holdings Limited China Medical System Holdings Limited

China Medical System Holdings Limited

0867

株式のランク #4732
Established in 1995 and headquartered in North Point, Hong Kong, China Medical... Established in 1995 and headquartered in North Point, Hong Kong, China Medical System Holdings Limited functions as an investment holding company with a primary focus on the development, marketing, and distribution of a wide array of pharmaceutical products throughout the People's Republic of China. The company's extensive portfolio addresses numerous therapeutic areas. Its cardiovascular offerings include Plendil for hypertension and stable angina, XinHuoSu for acute heart failure, and Imdur for coronary heart disease, chronic heart failure, and myocardial infarction prevention. For mental health and neurological support, it provides Deanxit to treat mild-to-moderate depression and anxiety, along with Parlodel tablets for endocrine and neuro system indications. Digestive and liver conditions are managed with products such as Ursofalk for gallstones and cholestatic liver disease, Salofalk for ulcerative colitis and Crohn's disease, Bioflor for diarrhea, Combizym for dyspepsia, and Ganfule capsules for primary liver cancer, plus MOVICOL for chronic constipation. The company also markets Augentropfen Stulln Mono eye drops for senile macula degeneration and asthenopia, Hirudoid for blunt trauma and superficial phlebitis, Elcatonin injection for osteoporosis, and Lamisil tablets for fungal infections. Respiratory issues are addressed by YiNuoShu, while infectious diseases benefit from DanShenTong capsules (for various infections like acne, tonsillitis, and boils) and YinlianQinggan granules for hepatitis. XiDaKang, a protein hydrolysate oral solution, is also part of its offerings. Beyond its pharmaceutical endeavors, the group is also actively involved in agriculture and livestock operations. China Medical System Holdings Limited operates as a subsidiary of Treasure Sea Limited.
株価
$1.30
最終同期: 2026-10-16
時価総額
$3.17B
変化(1日)
-2.21%
変化(1年)
-22.77%
国
HK
取引 China Medical System Holdings Limited (0867)

カテゴリー

Healthcare
China Medical System Holdings Limited(0867)のEPS
June 2026 時点のEPS TTM: $0.09
China Medical System Holdings Limitedの最新の財務報告と株価によると、同社の現在のEPS(TTM)は$0.09です。2023年末には、EPSは$0.14で、2022年のEPS$0.19と減少でした。
China Medical System Holdings LimitedのEPS履歴(2006から2026まで)
各年末時点のEPS
年 EPS 変化
2026 (TTM) $0.09 -0.22%
2024 $0.09 -33.67%
2023 $0.14 -28.22%
2022 $0.19 0.47%
2021 $0.19 22.93%
2020 $0.16 37.53%
2019 $0.11 5.48%
2018 $0.11 4.47%
2017 $0.10 30.05%
2016 $0.08 28.57%
2015 $0.06 -11.24%
2014 $0.07 61.77%
2013 $0.04 21.53%
2012 $0.04 38.98%
2011 $0.03 67.11%
2010 $0.02 29.91%
2009 $0.01 -93.06%
2008 $0.17 57.77%
2007 $0.11 98.51%
2006 $0.05 0.00%